SITC Resources

To support clinicians working at the front lines of the COVID-19 pandemic, the Society for Immunotherapy of Cancer (SITC) is advocating for the pharmaceutical industry, health authorities and institutional IRBs to continue to work creatively and collaboratively to expand access to IL-6-targeting therapies for their potential use in critically-ill patients with COVID-19.

Read More >>


The Society for Immunotherapy of Cancer (SITC) has issued a call for all COVID-19-related research to be made open-access across all biomedical journals, to further facilitate exchange of information during the Coronavirus pandemic.

Read More >>